Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2009-04-08
2010-10-26
Gambel, Phillip (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023500, C435S252300, C435S326000, C435S334000, C435S343000, C435S343100
Reexamination Certificate
active
07820807
ABSTRACT:
Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5463564 (1995-10-01), Agrafiotis et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5723322 (1998-03-01), Guettler et al.
patent: 5801227 (1998-09-01), Fanslow, III et al.
patent: 5901069 (1999-05-01), Agrafiotis et al.
patent: 6106835 (2000-08-01), Chang
patent: 6497876 (2002-12-01), Maraskovsky et al.
patent: 6632992 (2003-10-01), Hasegawa
patent: 7172759 (2007-02-01), Thomas et al.
patent: 7547438 (2009-06-01), Thomas et al.
patent: 2003/0022860 (2003-01-01), Melief et al.
patent: 99/61057 (1999-12-01), None
patent: 02/11763 (2002-02-01), None
Orkin et al., “Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy”, NIH, 1995.
Skolnick et al., Trends in Biotech., 18: 34 39, 2000.
Eck et al., Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Eds., 1996, pp. 77-101.
Verma et al., Nature 389: 239-242, 1997.
Bjorck, P. et al.; “CD40 Antibodies Defining Distinct Epitopes Display Qualitative Differences in Their Induction of B-Cell Differentiation”, Immunology, Blackwell Scientific Publications , GB, vol. 87, pp. 291-295, 1996. XP002930984 ISSN: 0019-2805.
Challa, A. et al.; “Epitope-dependent Synergism and Antagonism Between CD40 Antibodies and Soluble CD40 Ligand for the Regulation of CD23 Expression and IgE Synthesis in Human B Cells”; Allergy (Copenhagen), vol. 54, No. 6, pp. 576-583; Jun. 1999. XP002276806 ISSN: 0105-4538.
Dullforce, P. et al.; “Enhancement of T Cell-Independent Immune Responses In Vivo by CD40 Antibodies”; Nature Medicine Natu re Publishing Co., US, vol. 4, No. 1, pp. 88-91; Jan. 1998. XP009026323 ISSN: 1078-8956.
French, R. et al.; “CD40 Antibody Evokes a Cytotoxic T-cell Response That Eradicates Lymphoma and Bypasses T-cell Help”; Nature Medicine, Nature Publishing, CO, US, vol. 5, No. 5, pp. 548-553; May 1999. XP002159390 ISSN: 1078-8956.
Jeffrey A. Ledbetter, et al.; “Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed From the Variable Regions of mAb G28-5”; Critical Reviews in Immunology, vol. 17, Issue 1, pp. 427-435; 1997.
Zhao-hua Zhou et al.; “An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line”; Hybridoma, vol. 18, No. 6, pp. 471-478; 1999.
Zhao-hua Zhou et al.; “The obtaining of an anti-human CD40 mono-clonal antibody with special functions and the analysis of its biological effects”; Chinese Journal of Immunology, vol. 15, No. 12, pp. 529-533; 1999.
Hilkens, C. M. U. et al.: “Human Dendritic Cells Require Exogenous Interleukin-12-Inducing Factors to Direct the Development of Naive T-Helper Cells Toward the TH1 Phenotype”; Bllod, vol. 90, No. 5 Sep. 1, 1997: pp. 1920-1926.
Pound, J.D. et al.; “Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promtion of the cell cycle and homotypic adhesions in human B cells” International Immunology, vol. 11, No. 1, pp. 11-20.
Bjorck et al. “Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40.” Immunoloav. Nov. 1994;83(3):430-7.
Heath et al. “Monoclonal antibodies to murine CD40 define two distinct functional epitopes.” Eur. J. Immunol. 1994; 24 (8):1828-34.
Holder et al. “Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction.” Eur. J. Immunol. Sep. 1993; 23(9):2368-71.
Pellat-Deceunynck et al. “CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation.” Cancer Res. Apr. 15, 1996;56(8):1909-16.
Schwabe et al. “Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies.”Hybridoma. Jun. 1997;16 (3):217-26.
Valle et al. “Activation of human B lymphocytes through CD40 and interleukin 4.” Eur. J. Immunol. Aug. 1989;19 (8):1463-7.
Guerder et al., “A fail-safe mechanism for maintaining self-tolerance”, J. Exp. Med.176(2):553-564 (1992).
Bennett, S.R.M., et al., “Help for Cytotoxic T-Cell Responses is Mediated by CD40 Signaling”, Nature 393:478-480 (1998).
Schoenberger, S.P. et al., “T-Cell Help for Cytotoxic T-Lymphocytes is Mediated by CD40-CD40L Interactions”, Nature 393:480-483 (1998).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands”, Curro Opin. Immunol. 6 (3):407-13 (1994).
Alderson, et al., “CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40”, .J. Exp. Med. 178(2):669-674 (1993).
Caux, et al., “B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells”, J Exp Med. 180(5):1841-1847 (1994).
Riechmanna, L., et al., “Reshaping Human Antibodies for Therapy”, Nature 332: 323-327(1988).
Evans M. J., et al., “Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector That Replicates in COS and 293 Cells”, J. Immunol. Meth. 184: 123-138 (1995).
Tang, A. et al., “Suppression of Murine Allergic Contact Dermatitis by CTLA41g: Tolerance Induction of Th2 Responses Requires Additional Blockade of CD-40 Ligand”, J. Immunol. 157:117-125 (1996).
Ridge, J. P. et al., “A Conditioned Dendritic Cell Can Be a Temporal Bridge Between a CD4+ T-Helper and a T-Killer Cell”, Nature 393:474-477 (1998).
Caux, C. et al., “Activation of human dendritic cells through CD40 cross-linking” J Exp Med. 180(4):1263-1272 (1994).
Ngo et. al: “Computational Complexity, Proteing Structure Prediction, and the Levinthal Paradox” The Protein Folding Problem and Tertiary Structure Prediction. 1994 pp. 433, 492-495.
Skolnick et al.: From Genes to Protein Structure and Function: Novel Applications of the Commutational Approaches in the Genomic Era Trends in Biotech. 18:34-39 (2000).
Kuntz et al.: “Structure-based Strategies for Drug Design and Discovery” Science 257: 1078-1082 (1992).
Caux et al.: “Functional CD40 on B lymphocytes and Dendritic Cells” Research in Immunology 145(3):235-239 (1994).
Katira et al.: “B10.4 Identification for Co-operative Epitopes on CD40 Supports the Existence of a Second CD40 Ligand” In Leukocyte Typing V, Oxford University Press 1995, p. 554.
De Boer Mark
Res Pieter C. J. M.
Simons Peter J.
Thomas David
Gambel Phillip
Hoffmann & Baron , LLP
Pangenetics BV
LandOfFree
Gene constructs coding for CD40-binding activating antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene constructs coding for CD40-binding activating antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene constructs coding for CD40-binding activating antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4182062